Top Page
Sigma Healthcare Ltd
(Sydney:SIG)
Sigma Healthcare Ltd (SIG) vs. S&P 500 (SPY)
Sigma Healthcare Ltd Business Overview & Revenue Model
Sigma Healthcare Ltd Financial Statement Overview
| Breakdown | ||||
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 4.89B | 3.32B | 3.66B | 3.45B | 3.40B | Gross Profit |
| 334.05M | 189.82M | 224.07M | 199.42M | 210.61M | EBIT |
| -10.08M | 91.75M | -68.92M | -110.18M | -98.39M | EBITDA |
| 55.47M | 53.25M | 50.20M | 30.23M | 68.96M | Net Income Common Stockholders |
| -13.84M | 4.51M | 1.81M | -7.24M | 43.53M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 14.57M | 356.50M | 16.65M | 31.14M | 16.13M | Total Assets |
| 1.83B | 1.40B | 1.20B | 1.28B | 1.22B | Total Debt |
| 132.09M | 136.63M | 226.99M | 323.43M | 215.23M | Net Debt |
| 117.51M | -219.87M | 210.34M | 292.29M | 199.10M | Total Liabilities |
| 991.29M | 531.52M | 723.84M | 786.65M | 705.00M | Stockholders Equity |
| 837.86M | 870.77M | 475.92M | 487.19M | 513.67M |
| Cash Flow | Free Cash Flow | |||
| -323.50M | 37.25M | 113.34M | -60.48M | -64.56M | Operating Cash Flow |
| -315.59M | 41.97M | 142.74M | -46.28M | -13.13M | Investing Cash Flow |
| -1.60M | 5.73M | -28.60M | -16.59M | 124.36M | Financing Cash Flow |
| -24.73M | 295.82M | -116.94M | 128.89M | -265.71M |
Sigma Healthcare Ltd Technical Analysis
Sigma Healthcare Ltd Peers Comparison
Sigma Healthcare Ltd Corporate Events
Sigma Healthcare Ltd’s Sustainability Report for 2024/25 highlights the company’s commitment to sustainability and its recent merger with Chemist Warehouse. This merger is expected to strengthen Sigma’s market position and enhance its value chain, benefiting customers and the community. The report outlines Sigma’s governance, environmental initiatives, and approach to sustainability, reflecting its dedication to responsible business practices.
The most recent analyst rating on (AU:SIG) stock is a Buy with a A$3.45 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
Sigma Healthcare Ltd has released its Corporate Governance Statement for the financial year ending January 31, 2025, which outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations. The statement, which is available on the company’s website, confirms that Sigma Healthcare has followed the recommended governance practices, including board management roles and responsibilities, director appointment checks, and accountability of the company secretary. This release is significant as it underscores Sigma Healthcare’s commitment to transparency and robust governance, which is crucial for maintaining investor confidence and regulatory compliance.
The most recent analyst rating on (AU:SIG) stock is a Buy with a A$3.45 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
Sigma Healthcare Ltd has released its Corporate Governance Statement for 2024/25, highlighting its commitment to high standards of corporate governance and adherence to the ASX Corporate Governance Principles and Recommendations. Following its merger with Chemist Warehouse in February 2025, the company plans to review and update its corporate governance framework to align with the merged entity’s needs. The Board’s responsibilities include setting strategic goals, overseeing management, and ensuring risk management and legal compliance. The merger has also led to changes in the Board’s composition, with a mix of Executive and Non-Executive Directors.
The most recent analyst rating on (AU:SIG) stock is a Buy with a A$3.45 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
Sigma Healthcare Ltd’s Annual Report for 2024/25 outlines the company’s financial performance, operational highlights, and strategic initiatives. The report provides insights into Sigma’s efforts to strengthen its market position through business acquisitions and enhanced financial management. It also highlights the company’s commitment to maintaining robust financial health and delivering value to its stakeholders.
The most recent analyst rating on (AU:SIG) stock is a Buy with a A$3.45 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
Sigma Healthcare Ltd has released its Annual Report and other related documents for the year ending January 31, 2025, reflecting its position before merging with the Chemist Warehouse Group. The merger, completed in February 2025, prompts a review of the company’s reporting practices to align with the new entity, highlighting a significant transition in Sigma’s operations and strategic direction.
The most recent analyst rating on (AU:SIG) stock is a Buy with a A$3.45 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
Sigma Healthcare Ltd has announced a change in the director’s interest, with Damien Gance, the director, disposing of 126,500,000 ordinary shares through an off-market trade. This transaction impacts the holdings of the DGSR Family Foundation Pty Ltd, which now holds 127,329,615 ordinary shares, reflecting a strategic adjustment in the director’s financial interests within the company.
The most recent analyst rating on (AU:SIG) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
Sigma Healthcare Limited announced a trading update following its merger with Chemist Warehouse Group, revealing a 36% growth in Normalised EBIT for the nine months ending March 31, 2025, consistent with Chemist Warehouse’s performance for the first half of FY25. The merger is treated as a reverse acquisition for accounting purposes, with Chemist Warehouse as the accounting acquirer, and Sigma’s financial results for FY25 will include Chemist Warehouse’s financials from the merger date. The announcement highlights significant transaction costs and the impact of inter-company sales on earnings.
Sigma Healthcare Ltd has announced a significant change in the director’s interest, with Damien Gance disposing of 100,000,000 ordinary shares through an off-market trade. This transaction reduces the holdings of the DGSR Family Foundation Pty Ltd, for which Gance is the sole director and shareholder, potentially impacting the company’s shareholder structure and market perception.
Sigma Healthcare Limited announced that the Australian Securities and Investments Commission (ASIC) has granted extensions for holding its annual general meetings (AGMs). This extension allows Sigma to align its financial reporting with Chemist Warehouse’s financial year, facilitating a smoother integration following their merger. The extension periods enable Sigma to hold AGMs by 30 November each year, providing a consistent timeline for shareholder engagement and compliance with statutory obligations.
Sigma Healthcare Limited announced its financial results for the year ending January 31, 2025, marking its last as a standalone entity before merging with Chemist Warehouse Group. The company reported a significant increase in normalised revenue and EBIT, attributed to strategic operational execution and the successful onboarding of a new supply contract. The merger is expected to enhance Sigma’s market position, creating a leading wholesaler and retail franchisor with strong growth potential both in Australia and internationally.
Sigma Healthcare Ltd reported a significant increase in sales revenue by 45.7% for the year ending January 31, 2025, reaching $4.84 billion. Despite the revenue growth, the company experienced a net loss after tax of $12.9 million, attributed to a decrease in statutory EBIT and net tangible asset backing per share. The company declared no final dividend for the year, reflecting a cautious approach amid financial challenges.
Sigma Healthcare Limited has announced a merger that combines its retailing strengths with efficient supply chain capabilities, aiming to support ongoing network expansion. The merger is expected to generate significant cost synergies of $60 million annually by the fourth year, despite one-off costs of approximately $75 million. The company plans to leverage its advertising and marketing capabilities and explore growth through the rollout of Australian Franchise Network stores and offshore expansion, driven by an experienced management team.
Sigma Healthcare Ltd has announced the quotation of 17,850 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to enhance its market presence and provide additional value to its stakeholders through increased liquidity and potential capital growth.
State Street Corporation, through its subsidiaries, has notified that it has ceased to be a substantial holder in Sigma Healthcare Ltd as of February 14, 2025. This change in substantial holding could impact Sigma Healthcare’s shareholder composition and market perception, potentially influencing investor decisions and the company’s strategic direction.
Sigma Healthcare Ltd has announced the quotation of 1,482,422 ordinary fully paid securities on the ASX, effective from February 14, 2025. This development may enhance Sigma’s market position and liquidity, reflecting potential growth and operational expansion, which could have significant implications for investors and stakeholders.
Sigma Healthcare Ltd announced the quotation of 483,456 ordinary fully paid securities on the Australian Securities Exchange (ASX) following the exercise of options or conversion of other convertible securities. This development indicates a strategic move by Sigma Healthcare, potentially impacting its market position and offering new opportunities for its stakeholders.
Sigma Healthcare Ltd announced a change in the director’s interest, indicating significant movements in securities held by Director Vikesh Ramsunder. These changes include the acquisition and disposal of various shares and rights, reflecting part of the company’s employee incentive scheme and strategic adjustments post-merger with Chemist Warehouse. The issuance and conversion of rights, along with on-market disposals, are aimed at aligning executive incentives with company performance, potentially impacting Sigma’s market positioning and shareholder value.
Sigma Healthcare Ltd announced a change in the interest of its director, Damien Gance. On February 14, 2025, Gance disposed of 40,000,000 ordinary shares held indirectly through various trusts, impacting his total shareholding in the company. This disposal may reflect strategic financial decisions or adjustments in the director’s investment portfolio, potentially influencing stakeholders’ perception of the company’s financial health and future prospects.
Sigma Healthcare Ltd has announced a change in its board of directors, with Kathryn Spargo ceasing to be a director as of February 12, 2025. Spargo held direct and indirect interests in the company, with holdings of 349,949 fully paid ordinary shares directly and 369,730 indirectly through a self-managed superannuation fund. This change may impact the company’s governance and strategic direction, potentially affecting stakeholders’ interests.
Citigroup Global Markets Australia Pty Limited has ceased to be a substantial holder in Sigma Healthcare Ltd as of February 13, 2025. The changes in relevant interests were due to contracts entered into in the ordinary course of business, affecting the voting securities of the company. This shift in holding status could impact the company’s stakeholder dynamics and market perception.
The Vanguard Group, Inc., along with its controlled entities, has ceased to be a substantial holder of Sigma Healthcare Ltd as of February 13, 2025. Vanguard Group’s change in holding reflects a reduction of their voting power to 0.755%, which could impact the company’s shareholder dynamics and influence in decision-making processes.